Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea
Open Access
- 1 September 2017
- journal article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 32 (5), 890-899
- https://doi.org/10.3904/kjim.2015.406
Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that typically presents in the form of skin manifestations with or without lymph node and bone marrow involvement. Given its rarity and recent recognition as a distinct pathological entity, no standard of treatment exists for this aggressive disease and its prognosis is particularly dismal. We retrospectively analyzed clinical features and treatment outcomes of patients who were diagnosed with BPDCN between 2000 and 2014. Ten patients had a median age at diagnosis of 41 years (range, 18 to 79), and seven patients were male. Sites of disease involvement were the skin (n = 7), lymph node (n = 5), bone marrow (n = 2), liver (n = 2), spleen (n = 2), and soft tissue (n = 1). Intensified chemotherapy regimens such as hyperCVAD regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), and VPDL (vincristine, methylprednisolone, daunorubicin, L-asparaginase) were used as a first-line treatment. Although all patients treated with intensified chemotherapy showed an objective response (five patients with complete response) with median progression-free survival of 11.2 months (range 6.2 to 19.4), complete remission was not sustained for more than 2 years in any case. The response was relatively long-lived compared with previously reported CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, but the above regimens do not result in long-term remission. All patients treated with hyperCVAD or VPDL showed an objective response, but the duration of response was relatively short. Thus, the development of more effective induction as well as consolidation treatment strategy should be warranted to improve this rare disease entity.Keywords
Funding Information
- Samsung Biomedical Research Institute (GL1B30311)
- National Research Foundation of Korea (2014R1A2A1A11049853)
- Ministry of Education, Science and Technology
This publication has 23 references indexed in Scilit:
- Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter studyHaematologica, 2012
- Blastic Plasmacytoid Dendritic Cell Neoplasia (BPDC) in Elderly Patients: Results of a Treatment Algorithm Employing Allogeneic Stem Cell Transplantation with Moderately Reduced Conditioning IntensityTransplantation and Cellular Therapy, 2011
- Tumoral aspects of plasmacytoid dendritic cells: What do we know in 2009?Autoimmunity, 2010
- Plasmacytoid Dendritic CellsAdvances in Anatomic Pathology, 2009
- Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice?British Journal of Dermatology, 2009
- Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasmsBone Marrow Transplantation, 2006
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005
- Blastic NK-Cell Lymphomas (Agranular CD4+CD56+ Hematodermic Neoplasms)American Journal of Clinical Pathology, 2005
- What is CD4+CD56+ malignancy and how should it be treated?Bone Marrow Transplantation, 2003
- Identification of a leukemic counterpart of the plasmacytoid dendritic cellsBlood, 2001